Treatment of pleural malignancies by photo-induction combined to systemic chemotherapy: Proof of concept on rodent lung tumors and feasibility study on porcine chest cavities.

Details

Serval ID
serval:BIB_B45D57A2CB25
Type
Article: article from journal or magazin.
Collection
Publications
Title
Treatment of pleural malignancies by photo-induction combined to systemic chemotherapy: Proof of concept on rodent lung tumors and feasibility study on porcine chest cavities.
Journal
Lasers In Surgery and Medicine
Author(s)
Wang X., Gronchi F., Bensimon M., Mercier T., Decosterd L.A., Wagnières G., Debefve E., Ris H.B., Letovanec I., Peters S., Perentes J.Y.
ISSN
1096-9101 (Electronic)
ISSN-L
0196-8092
Publication state
Published
Issued date
2015
Peer-reviewed
Oui
Volume
47
Number
10
Pages
807-816
Language
english
Notes
Publication types: Journal Article
Publication Status: ppublish
Abstract
BACKGROUND: Low-dose, Visudyne®-mediated photodynamic therapy (photo-induction) was shown to selectively enhance tumor vessel transport causing increased uptake of systemically administered chemotherapy in various tumor types grown on rodent lungs. The present experiments explore the efficacy of photo-induced vessel modulation combined to intravenous (IV) liposomal cisplatin (Lipoplatin®) on rodent lung tumors and the feasibility/toxicity of this approach in porcine chest cavities.
MATERIAL AND METHODS: Three groups of Fischer rats underwent orthotopic sarcoma (n = 14), mesothelioma (n = 14), or adenocarcinoma (n = 12) implantation on the left lung. Half of the animals of each group had photo-induction (0.0625 mg/kg Visudyne®, 10 J/cm(2) ) followed by IV administration of Lipoplatin® (5 mg/kg) and the other half received Lipoplatin® without photo-induction. Then, two groups of minipigs underwent intrapleural thoracoscopic (VATS) photo-induction (0.0625 mg/kg Visudyne®; 30 J/cm(2) hilum; 10 J/cm(2) apex/diaphragm) with in situ light dosimetry in combination with IV Lipoplatin® administration (5 mg/kg). Protocol I (n = 6) received Lipoplatin® immediately after light delivery and Protocol II (n = 9) 90 minutes before light delivery. Three additional animals received Lipoplatin® and VATS pleural biopsies but no photo-induction (controls). Lipoplatin® concentrations were analyzed in blood and tissues before and at regular intervals after photo-induction using inductively coupled plasma mass spectrometry.
RESULTS: Photo-induction selectively increased Lipoplatin® uptake in all orthotopic tumors. It significantly increased the ratio of tumor to lung Lipoplatin® concentration in sarcoma (P = 0.0008) and adenocarcinoma (P = 0.01) but not in mesothelioma, compared to IV drug application alone. In minipigs, intrapleural photo-induction combined to systemic Lipoplatin® was well tolerated with no toxicity at 7 days for both treatment protocols. The pleural Lipoplatin® concentrations were not significantly different at 10 and 30 J/cm(2) locations but they were significantly higher in protocol I compared to II (2.37 ± 0.7 vs. 1.37 ± 0.7 ng/mg, P  < 0.001).
CONCLUSION: Visudyne®-mediated photo-induction selectively enhances the uptake of IV administered Lipoplatin® in rodent lung tumors. Intrapleural VATS photo-induction with identical treatment conditions combined to IV Lipoplatin chemotherapy is feasible and well tolerated in a porcine model. Lasers Surg. Med. 47:807-816, 2015. © 2015 Wiley Periodicals, Inc.
Keywords
Adenocarcinoma/drug therapy, Animals, Antineoplastic Agents/pharmacokinetics, Antineoplastic Agents/therapeutic use, Antineoplastic Combined Chemotherapy Protocols/therapeutic use, Cell Line, Tumor, Cisplatin/pharmacokinetics, Cisplatin/therapeutic use, Drug Administration Schedule, Feasibility Studies, Lung Neoplasms/drug therapy, Male, Mesothelioma/drug therapy, Neoplasm Transplantation, Photochemotherapy/methods, Photosensitizing Agents/pharmacokinetics, Photosensitizing Agents/therapeutic use, Porphyrins/pharmacokinetics, Porphyrins/therapeutic use, Rats, Rats, Inbred F344, Sarcoma/drug therapy, Swine, Treatment Outcome
Pubmed
Web of science
Create date
07/10/2015 7:52
Last modification date
20/08/2019 15:22
Usage data